品牌现货直购
供应商:我要出现这里






查看所有供应商和价格请点击:

51264-14-3生产厂家

51264-14-3价格

51264-14-3

51264-14-3结构式
51264-14-3结构式
  • 常用中文名:安吖啶
  • 常用英文名:Amsacrine
  • CAS号:51264-14-3
  • 分子式:C21H19N3O3S
  • 分子量:393.459
  • 相关类别: 原料药 抗肿瘤药 抗代谢类抗肿瘤药
  • 发布时间:2018-08-29 11:04:36
  • 更新时间:2024-01-02 15:19:58
  • Amsacrine 是肿瘤细胞 DNA 嵌入剂,还能抑制拓扑异构酶 II。

化源商城直购

中文名 安吖啶
英文名 amsacrine
中文别名 N-[4-(9-吖啶基氨基)-3-甲氧基苯基]甲磺酰胺
安啶
M-AMSA 溶液
英文别名 m-AMSA
meta-Amsacrine
Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-
Amsacrine
4'-(Acridinylamino)methanesulfon-m-anisidide
Amsidyl
AMSA P-D
Amekrin
EINECS 257-094-3
AMSA, M-
Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)-
Amsine
Amsidine
N-[4-(9-Acridinylamino)-3-methoxuphenyl]methanesulfonamide
N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide
N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide
N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
描述 Amsacrine 是肿瘤细胞 DNA 嵌入剂,还能抑制拓扑异构酶 II。
相关类别
靶点

Topoisomerase II

体外研究 Amsacrine以浓度依赖性方式阻断HEK 293细胞和非洲爪蟾卵母细胞中的HERG电流,IC50值分别为209.4 nm和2.0μM。 Amsacrine引起激活(-7.6 mV)和失活(-7.6 mV)的电压依赖性的负向变化。通过amsacrine的HERG当前阻滞不依赖于频率[1]。对不同浓度m-AMSA的正常人淋巴细胞的体外研究显示,染色体畸变水平增加,范围从8%到100%,并且增加SCE,范围是研究的最低浓度的正常值的1.5倍(0.005μg/ mL)至正常值的12倍(0.25μg/ mL)[3]。 Amsacrine诱导的U937细胞凋亡的特征是caspase-9和caspase-3活化,细胞内Ca2 +浓度增加,线粒体去极化和MCL1下调。 Amsacrine通过降低其稳定性诱导MCL1下调。此外,amsacrine处理的U937细胞显示AKT降解和Ca2 +介导的ERK失活[4]。
体内研究 在用不同剂量的安吖啶(0.5-12mg/kg)治疗的动物中,用9和12mg/kg治疗后,微核多色红细胞的频率显着增加。此外,本研究首次表明,amsacrine具有高致裂性发生率和低致气性发生率,而nocodazole在体内有丝分裂期具有高致气性和低致裂性发生率[2]。
动物实验 在三个独立的实验中研究了Amsacrine。在第一个实验中,通过腹膜内注射0.5,1.5和4.5mg / kg的amsacrine处理动物,并在处理后24小时取样骨髓。在此采样时间的初步阴性MN结果导致使用30小时的采样时间用于安吖啶。因此,在第二个实验中,用0.5,1.5和4.5mg / kg的amsacrine处理小鼠,并在处理后30小时取样骨髓。通过参考早期研究选择安吖啶的剂量和采样时间,并且所选剂量在用于人化学疗法的剂量范围内。结果再次表明,小鼠骨髓中的微核率不受任何选定剂量的试验剂处理的影响,在30小时取样时间,因此,在第三个实验中,小鼠用6,9处理治疗后24和30小时取样12mg / kg的amsacrine和骨髓。
参考文献

[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94.

[2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33.

[3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97.

[4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19

密度 1.4±0.1 g/cm3
沸点 563.0±60.0 °C at 760 mmHg
熔点 230-240ºC
分子式 C21H19N3O3S
分子量 393.459
闪点 294.3±32.9 °C
精确质量 393.114716
PSA 88.70000
LogP 2.12
外观性状 白色固体
蒸汽压 0.0±1.5 mmHg at 25°C
折射率 1.723
储存条件

保持贮藏器密封、储存在阴凉、干燥的地方,确保工作间有良好的通风或排气装置

稳定性

如果遵照规格使用和储存则不会分解,未有已知危险反应

计算化学

1.疏水参数计算参考值(XlogP):4

2.氢键供体数量:2

3.氢键受体数量:6

4.可旋转化学键数量:5

5.互变异构体数量:2

6.拓扑分子极性表面积88.7

7.重原子数量:28

8.表面电荷:0

9.复杂度:601

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

更多

1. 性状:未确定

2. 密度(g/mL,25ºC):未确定

3. 相对蒸汽密度(g/mL,空气=1): 未确定

4. 熔点(ºC):未确定

5. 沸点(ºC):未确定

6. 沸点(ºC,12mm hg):未确定

7. 折射率:未确定

8. 闪点(°C):未确定

9. 比旋光度(ºC):未确定

10. 自燃点或引燃温度(ºC): 未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:未确定

毒理学数据:

急性毒性LD50雄小鼠,雌小鼠(ml/m2):810,729口服。
盐酸安吖啶(Amsacrine Hydrochloride):C21H19N3O3S.HCL.。结晶,熔点197~199℃。急性毒性LD50小鼠(mg/kg):约60腹腔注射。
甲磺酸安吖啶(Amsacrine HydrochlorideC21H19N3O3S.CH3SO3H结
晶,熔点292~293℃。急性毒性LD50小鼠(mg/kg):约24腹腔注射。

生态学数据:

对水是稍微有危害的不要让未稀释或大量的产品接触地下水、水道或者污水系统,若无政府许可,勿将材料排入周围环境

CHEMICAL IDENTIFICATION

RTECS NUMBER :
PB1080000
CHEMICAL NAME :
Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-
CAS REGISTRY NUMBER :
51264-14-3
BEILSTEIN REFERENCE NO. :
0500176
LAST UPDATED :
199801
DATA ITEMS CITED :
58
MOLECULAR FORMULA :
C21-H19-N3-O3-S
MOLECULAR WEIGHT :
393.49
WISWESSER LINE NOTATION :
T C666 BNJ IMR BO1 DMSW1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
5405 ug/kg/3H-C
TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human
DOSE/DURATION :
12 mg/kg
TOXIC EFFECTS :
Vascular - thrombosis distant from injection site Gastrointestinal - nausea or vomiting Blood - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
53420 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
15470 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
110 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
33700 ug/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
50 mg/kg
TOXIC EFFECTS :
Behavioral - food intake (animal) Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
6250 ug/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
10400 ug/kg
TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
546 mg/kg/13W-I
TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
90 mg/kg/24W-I
TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - changes in testicular weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
69250 ug/kg/5D-I
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Blood - pigmented or nucleated red blood cells Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
125 mg/kg/5D-I
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
1950 ug/kg/5D-I
TOXIC EFFECTS :
Blood - hemorrhage Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
13 mg/kg/5D-I
TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
30 mg/kg/24W-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Gastrointestinal - tumors Skin and Appendages - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
6486 ug/kg
SEX/DURATION :
male 3 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
8 mg/kg
SEX/DURATION :
female 6-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
15 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
DNA damage
TYPE OF TEST :
Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :
DNA damage
TEST SYSTEM :
Mammal - species unspecified Lymphocyte
DOSE/DURATION :
54 umol/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 38,1300,1978 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X6337 No. of Facilities: 7 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 14 (estimated) No. of Female Employees: 14 (estimated)

危险品运输编码 UN 3249
包装等级 III
危险类别 6.1(b)
海关编码 2935009090
【方法1】
邻甲氧基对硝基苯胺和酰氯反应,对氨基酰胺化进行保护,还原硝基为氨基,以甲磺酰氯对该氨基进行酰化使形成甲磺酰胺基,再选择性水解脱去1位氨基上的保护基,最后和9-氯吖啶反应,得到安吖啶。
海关编码 2935009090
中文概述 2935009090 其他磺(酰)胺. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:6.5% 普通关税:35.0%
申报要素 品名, 成分含量, 用途
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%